249 related articles for article (PubMed ID: 15312364)
1. [Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
Hao GY; Zhang WD; Chen YH; Zhang DX; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):283-6. PubMed ID: 15312364
[TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
[TBL] [Abstract][Full Text] [Related]
4. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
Cascorbi I; Roots I; Brockmöller J
Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma].
Lei D; Pan X; Guo C; Xu F; Zhang L; Liu D; Luan X
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):154-6. PubMed ID: 12015038
[TBL] [Abstract][Full Text] [Related]
6. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study.
Filiadis IF; Georgiou I; Alamanos Y; Kranas V; Giannakopoulos X; Lolis D
J Urol; 1999 May; 161(5):1672-5. PubMed ID: 10210437
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study.
Wang CY; Jones RF; Debiec-Rychter M; Soos G; Haas GP
Anticancer Res; 2002; 22(6B):3529-35. PubMed ID: 12552951
[TBL] [Abstract][Full Text] [Related]
8. Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors?
Ouerhani S; Rouissi K; Marrakchi R; Riadh Ben Slama M; Sfaxi M; Ayed M; Chebil M; Elgaaied A
Bull Cancer; 2009 May; 96(5):E23-9. PubMed ID: 19467981
[TBL] [Abstract][Full Text] [Related]
9. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
Stern MC; Johnson LR; Bell DA; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
[TBL] [Abstract][Full Text] [Related]
10. N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population.
Kocabaş NA; Sardaş S; Cholerton S; Daly AK; Karakaya AE
Int J Toxicol; 2004; 23(1):25-31. PubMed ID: 15162844
[TBL] [Abstract][Full Text] [Related]
11. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
Inatomi H; Katoh T; Kawamoto T; Matsumoto T
Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
[TBL] [Abstract][Full Text] [Related]
12. GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study.
Zupa A; Sgambato A; Bianchino G; Improta G; Grieco V; LA Torre G; Campisi B; Traficante A; Aieta M; Cittadini A
Anticancer Res; 2009 May; 29(5):1709-14. PubMed ID: 19443391
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
[TBL] [Abstract][Full Text] [Related]
14. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer.
Giannakopoulos X; Charalabopoulos K; Baltogiannis D; Chatzikiriakidou A; Alamanos Y; Georgiou I; Evangelou A; Agnantis N; Sofikitis N
Anticancer Res; 2002; 22(6B):3801-4. PubMed ID: 12552997
[TBL] [Abstract][Full Text] [Related]
15. A slow acetylator genotype associated with an increased risk of advanced cervical cancer.
Costa S; Medeiros R; Vasconcelos A; Pinto D; Lopes C
J Cancer Res Clin Oncol; 2002 Dec; 128(12):678-82. PubMed ID: 12474054
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
17. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
Belogubova EV; Kuligina ESh; Togo AV; Karpova MB; Ulibina JM; Shutkin VA; Hanson KP; Popowski K; Mosyagin I; Cascorbi I; Hirvonen A; Imyanitov EN
Cancer Lett; 2005 Apr; 221(2):177-83. PubMed ID: 15808403
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction.
Green J; Banks E; Berrington A; Darby S; Deo H; Newton R
Br J Cancer; 2000 Aug; 83(3):412-7. PubMed ID: 10917561
[TBL] [Abstract][Full Text] [Related]
19. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
[TBL] [Abstract][Full Text] [Related]
20. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
